Evidence · Clinical Trials
Muse Cell Clinical Trials & Evidence
A quick physician map to the Muse stem cell clinical-trial landscape and how to read the evidence when evaluating vendors or protocols.
Active indications in trials
- Acute myocardial infarction
- Ischemic stroke
- Spinal cord injury
- Epidermolysis bullosa
- ARDS / acute respiratory distress
- Amyotrophic lateral sclerosis (early work)
Most human trials of allogeneic Muse cell products (e.g. CL2020) have originated in Japan, sponsored by Life Science Institute. Investigator-initiated work continues globally in orthopedic and longevity applications.
Key Muse cell studies
Direct links to peer-reviewed publications and trial reports on Multilineage Differentiating Stress Enduring (Muse) cells:
- Randomized placebo-controlled trial of CL2020 in subacute ischemic stroke — Journal of Cerebral Blood Flow & Metabolism, 2023
- Safety and efficacy of human Muse cell-based product for acute myocardial infarction — Circulation Journal, 2020
- Safety and feasibility of allogenic-Muse cells in cervical traumatic spinal cord injury — Stem Cell Research & Therapy, 2024
- Intravenous allogeneic Muse cells in dystrophic epidermolysis bullosa — Journal of the European Academy of Dermatology and Venereology, 2021
- Donor Muse cell treatment without HLA-matching or immunosuppressants — Stem Cell Reviews and Reports, 2024
- Endogenous reparative pluripotent Muse cells and immune privilege — World Journal of Stem Cells, 2022
How to evaluate Muse cell evidence
- Confirm the product is a defined SSEA-3+ Muse population, not bulk MSC
- Check dose, route, and patient selection criteria
- Look for tumorigenicity monitoring in follow-up
- Distinguish sponsor-run trials from independent replication
- Confirm publication in peer-reviewed journals, not just press releases
FAQ
Are there published Muse cell clinical trials?
Yes. CL2020 (Life Science Institute) has advanced Muse cell products through Japanese clinical trials in acute myocardial infarction, stroke, epidermolysis bullosa, spinal cord injury, and ARDS. Peer-reviewed publications describe the trial designs and interim outcomes.
Where can I read the primary literature on Muse cells?
Search PubMed for 'Muse cells' or 'SSEA-3 pluripotent stem cells' — Professor Mari Dezawa's group has published extensively since the original 2010 characterization. Review articles summarize homing, differentiation, and clinical pipeline.
How should physicians evaluate Muse cell evidence?
Look for: defined SSEA-3+ product, dose and route, patient selection criteria, safety endpoints, tumorigenicity monitoring, and independent replication. Distinguish company-sponsored trials from investigator-initiated work.
Related reading
Ready to translate the evidence into practice?
Watch the Summit talks where physicians walk through their protocols, or request info about bringing MuseCells and MuseExosomes into your clinic.